Article

Large Study Finds Predictors of Depression in Lupus

Recent diagnosis of lupus and use of high doses of prednisone are among the chief predictors of depression in patients with SLE.

Huang X, Magder LS, Petri M. Predictors of incident depression in SLE.  Journal of Rheumatology (2014) 41:1823-1833. doi: 10.3899/jrheum.140111. Online Aug 15.

Results have been inconsistent from previous studies looking for predictors of depression in patients with systemic lupus erythematosus (SLE). Here, analysis of 1,609 patients from the Hopkins Lupus Cohort shows a higher risk for incident depression among patients if they have a recent diagnosis of SLE or a recent period of cutaneous activity, a history of longitudinal myelitis, or if they currently take high doses of steroids.

Patients were enrolled only if they had no previous history of depression. During a total follow-up of 9,487 person-years, the authors recorded 282 cases of incident depression - a rate of 17%, at the low end of the range of previously reported prevalences of depression in SLE (2% to 60%).

Compared to patients who don’t take prednisone, the Hopkins data show that the rate of incident depression is 2.3 times higher (P = 0.0002) among patients who take 20-39 mg/day and 3.1 times higher (P = 0.0001) among those taking at least 40 mg/day. Other independent predictors of depression included a recent SLE diagnosis, non-Asian ethnicity, disability, cutaneous activity, and longitudinal myelitis. After controlling for prednisone use, the researchers found that global disease activity (SELENA-SLEDAI) was not a significant predictor.

“Because these higher doses of prednisone are generally used in patients with SLE with higher disease activity, especially renal, central nervous system, and hematologic involvement, " the authors state, "our results reinforce the need for noncorticosteroid approaches to control SLE activity, to avoid inducing depression.”

 

 

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.